HCIT,
This is a good point. I’d love the 60 day data as soon as possible as well.
Concerning 3rd doses, of course it doesn’t jive with CD12 trial design. But with half-life and receptor occupancy in HIV, we have started to look at a once per month subQ injection, versus a once per week.
Two doses at once per month (assuming half life in vivo and receptor occupancy) equals 60 days. So I think we remain effective in CD12 at 60 days.
Three and four doses, In my opinion, will have beneficial effect for long long-haulers, C19, HIV (obviously), and any condition requiring immune modulation over time. Specific targeted data over time will indicate dosages required over time and for which indications. Dr P’s assays will come in handy. Or others. IMHO.
GLTU
Chazzle
This is a good point. I’d love the 60 day data as soon as possible as well.
Concerning 3rd doses, of course it doesn’t jive with CD12 trial design. But with half-life and receptor occupancy in HIV, we have started to look at a once per month subQ injection, versus a once per week.
Two doses at once per month (assuming half life in vivo and receptor occupancy) equals 60 days. So I think we remain effective in CD12 at 60 days.
Three and four doses, In my opinion, will have beneficial effect for long long-haulers, C19, HIV (obviously), and any condition requiring immune modulation over time. Specific targeted data over time will indicate dosages required over time and for which indications. Dr P’s assays will come in handy. Or others. IMHO.
GLTU
Chazzle
5
